VIDAZA

Azacitidine, also known as Vidaza or Onureg, is a chemotherapy drug used to treat chronic myelomonocytic leukaemia (CMML).

The subset analysis of the AZA-001 study revealed that patients treated with VIDAZA had a median overall survival of 24.5 months, whereas those treated with CCR had a median overall survival of 16.0 months (p=0.005). Furthermore, 50 percent of AML patients treated with VIDAZA survived for at least two years, while only 16 percent of AML patients treated with CCR achieved the same outcome.

Although your hair may become thinner, it is improbable that you will experience complete hair loss. Typically, hair loss begins after your initial or subsequent treatment. However, it is typically temporary, and your hair will typically regrow after treatment is completed.

If you experience any of the following serious side effects, it is important to notify your doctor immediately: excessive bleeding or bruising, chest pain, pain in muscles or joints, muscle cramps, irregular heartbeat, changes in mental or mood state (such as increased anxiety), dark urine, and yellowing of the eyes or skin.

If you experience any unusual bleeding, please contact your care team as this medication may heighten your risk of bruising or bleeding. It is important to exercise caution when brushing or flossing your teeth or using a toothpick, as there is a possibility of increased susceptibility to infection or bleeding. Additionally, it is crucial to inform your dentist about your current medication regimen if you require any dental procedures.

No, Medicare prescription drug plans do not cover azacitidine.

The 5-year relative survival rate for individuals aged 20 and above diagnosed with AML is 28%, while for those under the age of 20, it is 69%.

Vincristine or the liposomal form, Marqibo, Daunorubicin or doxorubicin, Cytarabine, L-asparaginase or PEG-L-asparaginase (pegaspargase or Oncaspar), 6-mercaptopurine, Methotrexate, Cyclophosphamide, and Prednisone.

Vidaza injection is prescribed for the treatment of specific bone marrow cancers and blood cell disorders. It is available in single-dose injection vials containing 100 mg of lyophilized powder.

Intensive chemotherapy has the potential to induce remission in individuals, wherein no evidence of MDS is observed when examining bone marrow samples under a microscope. However, this remission is typically temporary, as without additional treatment, MDS tends to recur.

In MDS patients, 14% achieved complete remission (CR), while the overall response rate was 27%. The estimated overall survival (OS) at 12 months was 75%.

In AML patients, 7% achieved CR, while the overall response rate was 20%. The estimated OS at 12 months was 60%.

In CMML patients, 10% achieved CR, while the overall response rate was 20%. The estimated OS at 12 months was 75%.

For individuals with acute myeloid leukemia (AML), chemotherapy is typically the primary form of treatment, although alternative treatments may also be utilized. In cases where individuals have other significant health concerns, less aggressive chemotherapy may be suggested. However, age alone is not a deterrent for receiving chemotherapy.

The chemotherapy drug hydroxyurea, also known as Hydrea®, is administered orally and is effective in rapidly reducing elevated white blood cell counts and reducing the size of an enlarged spleen in patients with chronic myeloid leukemia (CML). Other drugs that may be used in the treatment of CML include cytarabine (Ara-C), busulfan, cyclophosphamide (Cytoxan®), and vincristine (Oncovin®).

The methyl transferase inhibitor 5 Azacytidine, which specifically targets epigenetic changes in MDS, has demonstrated effectiveness in up to 60% of patients in a Phase III randomized controlled trial when compared to best supportive care. As a result, it has been approved by the US Food and Drug Administration for use in all patients.

Multiple studies and clinical trials have examined the effectiveness of azacitidine and decitabine, finding that they have overall response rates ranging from 30% to 60%. Additionally, the median Overall Survival (OS) for patients treated with these drugs ranges from 12 to 37 months.

You should only take this medicine under the direct supervision of your doctor.

Patients with lower-risk MDS typically live for about 3 to 10 years, while those with higher-risk disease have a median survival of less than 3 years.

Regardless of whether a person is receiving other treatments for MDS, supportive care is crucial. If additional treatment is necessary, chemotherapy drugs like azacitidine (Vidaza) or decitabine (Dacogen) are often the primary options, particularly for patients with lower-risk forms of MDS.

Previous research has shown that the use of Vidaza alone resulted in a 40% response rate among patients with TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Out of those responders, 20% achieved complete remission. However, the response duration was short and the overall survival rate was only six months.

Azacitidine, also known as Vidaza®, belongs to a group of medications called hypomethylating agents. These drugs are effective in inhibiting the proliferation of abnormal bone marrow stem cells. Notably, Azacitidine was the first medication to receive FDA approval for the treatment of MDS.

You may undergo this treatment every 4 weeks as advised by your doctor. Typically, the treatment should be administered for a minimum of four cycles. If your condition does not improve and you do not experience severe side effects, your doctor may consider increasing your dosage of azacitidine after two cycles.

The price of Vidaza injectable powder for injection 100 mg can vary depending on the pharmacy you go to, but it is typically around $626 for a supply of 1 powder for injection.

Three other drugs, imatinib, dasatinib, and nilotinib, have been approved in the last decade. However, the three new drugs, ponatinib, omacetaxine, and bosutinib, have been priced at exorbitant rates. Ponatinib costs $138,000 per year, omacetaxine costs $28,000 for induction and $14,000 per maintenance course, and bosutinib costs approximately $118,000 per year.

IPSS-R Risk GroupMedian Survival
Very Low8.8 years
Low5.3 years
Intermediate3 years
High1.6 years

Discover more information about azacitidine injection, a generic drug. The average price for 30 Suspension Reconstituted(s), each containing 100MG of the generic azacitidine, is $4,288.14. However, you have the opportunity to purchase azacitidine at a discounted rate of $2,431.50 by utilizing the NowPatient Rx Advantage Card, resulting in a savings of 43%.

In the month of diagnosis, acute leukemia patients have the highest average allowed spending, which is just under $120,000. On the other hand, multiple myeloma is the second most expensive cancer in terms of average allowed spending per patient, with a cost of $28,000.

In a study conducted in 2009, researchers reviewed the cases of 41 patients with MDS and marrow fibrosis who were treated with azacitidine. The overall response rate was determined to be 63%, with 7% achieving complete remission, 20% achieving partial remission, and 36% achieving hematologic improvement. The treatment was generally well tolerated, with the most commonly reported side effects being nausea, vomiting, diarrhea, and cytopenia. This study was conducted by Juvvadi et al. in 2007.

VIDAZA is administered in treatment cycles every 28 days, as recommended by your doctor. It may take 4 to 6 months of continuous treatment for noticeable improvement. If treatment is discontinued, symptoms may reappear.

Symptoms include a lack of desire to eat, weight loss, difficulty passing stool, abdominal discomfort, and digestive issues. Additionally, there may be the presence of cold sores or bleeding from the gums. Other symptoms may include the appearance of red or purple, flat, pinhead-sized spots under the skin, itching, a rash, bruising, redness of the skin, soreness and swelling at the injection site, and unusual hair loss or thinning.

The VIDAZA solution should be given intravenously. The entire dose should be administered within 10 to 40 minutes. It is important to complete the administration within 1 hour after reconstituting the VIDAZA vial.

WPSS Risk Group Median Survival Risk of AML (within 5 years)

Very low: 11.8 years, 3%
Low: 5.5 years, 14%
Intermediate: 4 years, 33%
High: 2.2 years, 54%

No, Medicare prescription drug plans do not cover azacitidine.

Transformation, also known as the development of acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells, can occur in some individuals with MDS. The timeframe for this transformation can range from a few months to several years.

In many cases, acute myeloid leukemia (AML) will enter a state of remission following the initial treatment. However, there are instances where the disease may not fully disappear or may relapse after a period of remission. In such cases, alternative treatments can be explored, provided that the individual’s health allows for it.

According to the data, patients who were treated with VENCLEXTA + azacitidine had a higher survival rate at 15 months compared to those who received azacitidine alone, with half of the patients still alive. However, it is important to note that VENCLEXTA may not be effective for all individuals. Additionally, the use of VENCLEXTA can lead to serious side effects such as tumor lysis syndrome, low white blood cell count, and infections.